Any current/future new fundraising through debt or equity?

Currently, the company is in the growth stage and acknowledges some initial challenges with financing. Receivables and payables are within a healthy range, but inventory levels are high due to last year's bad season, which they expect to clear by September to December. Regarding CAPEX and expansion, discussions on financing methods are ongoing, with plans to fund expansion mostly through debt or internal resources. There is no explicit mention of an immediate equity fundraising. The company prefers not to dilute shareholders at the current stock price and is considering financing options to ma

Any current/future capex/capital investment/strategic investment?

The company is currently planning CAPEX but details are still under discussion regarding financing. Expansion is expected to be financed either through debt or internal resources. Strategic investments include opening new branches in international markets and focusing on regulatory registrations in countries like Thailand, Mexico, Taiwan, Brazil, EU, and Australia. Investments are ongoing in South India with a significant team presence being established. There is a focus on product registrations and international patents to support future growth. Marketing and farmer engagement expenses are in

Future growth expectations in sales/revenue/volumes?

The company expects sales growth of 15-20% in FY25. Branded sales are increasing while institutional sales and trading are reducing. New patented products are key growth drivers, contributing about 25% of business and expected to rise to 30%. Recent product launches aim for high turnover, with some products targeting over ₹100 crore annually within 2-3 years. Sales volumes have increased by about 21% despite a 19% price erosion. Expansion into international markets, with registrations in countries like Thailand, Mexico, Taiwan, Brazil, EU, and Australia, expected to contribute to growth by 202

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a revenue growth of 15-20% in FY25 with EBITDA margins in the range of 16-17% for the full year. Patented, high-margin products launched recently are seen as key growth drivers for both top line and bottom line. New product launches typically generate 60-70 crores sales in year 1, potentially doubling in year 2, and reaching around 200 crores by year 3. Close to 25-30% of business is expected to come from new products in future years. Management is confident of achieving consistent EBITDA margins of 15-17% from Q2 onwards. Earnings per share (EPS) is expected to i

IN US

Sale is live|00:00:00left today

Best Agrolife LtdQ2 FY24Fertilizers & Agrochemicals

Best Agrolife Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹15.5P/E: 28.8Market Cap: ₹697 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects sales growth of 15-20% in FY25.
→Branded sales are increasing while institutional sales and trading are reducing.
→New patented products are key growth drivers, contributing about 25% of business and expected to rise to 30%.
→Recent product launches aim for high turnover, with some products targeting over ₹100 crore annually within 2-3 years.
→Sales volumes have increased by about 21% despite a 19% price erosion.
→Expansion into international markets, with registrations in countries like Thailand, Mexico, Taiwan, Brazil, EU, and Australia, expected to contribute to growth by 2025.
→First-half typically accounts for about 65% of annual business, with the second half improving due to new products and better market conditions.
→Efforts continue to reduce trading sales and focus on higher-margin branded products for sustainable revenue growth.

Margin guidance

Category 3

→The company expects a revenue growth of 15-20% in FY25 with EBITDA margins in the range of 16-17% for the full year.
→Patented, high-margin products launched recently are seen as key growth drivers for both top line and bottom line.
→New product launches typically generate 60-70 crores sales in year 1, potentially doubling in year 2, and reaching around 200 crores by year 3.
→Close to 25-30% of business is expected to come from new products in future years.
→Management is confident of achieving consistent EBITDA margins of 15-17% from Q2 onwards.
→Earnings per share (EPS) is expected to improve as higher inventory is liquidated and branded business grows.
→The company anticipates better H2 performance compared to previous years due to favorable monsoon and expanded markets.
→Long-term, individual patented molecules could contribute 100+ crores annually after 3 years of launch.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, the company is in the growth stage and acknowledges some initial challenges with financing.
→Receivables and payables are within a healthy range, but inventory levels are high due to last year's bad season, which they expect to clear by September to December.
→Regarding CAPEX and expansion, discussions on financing methods are ongoing, with plans to fund expansion mostly through debt or internal resources.
→There is no explicit mention of an immediate equity fundraising.
→The company prefers not to dilute shareholders at the current stock price and is considering financing options to maintain a stable balance sheet.
→The management indicated that any CAPEX will depend on the outcomes of financing discussions.
→Overall, the approach is cautious, focusing on managing growth and balance sheet stability without confirming any imminent fundraising.

Order book

- The transcript does not explicitly mention current or expected order book or pending orders. - However, discussions indicate a positive outlook on future sales, particularly in the 2nd and 3rd quarters, driven by new patented product launches and better seasonal conditions. - Inventory issues from previous periods are expected to be largely cleared by end of Q3, supporting smoother sales. - The company anticipates good market performance in upcoming quarters, bolstered by expanding branded business and international registrations. - Management is hopeful of achieving revenue growth in FY25 in the range of 15-20%. - EBITDA margins are expected to improve to 15-17% going forward. - International registrations and new product launches are likely to contribute to future order inflows, with results visible mostly by 2025-end. No specific numeric data related to orderbook or pending orders is provided in the transcript.

Capex plans

Yes

→The company is currently planning CAPEX but details are still under discussion regarding financing.
→Expansion is expected to be financed either through debt or internal resources.
→Strategic investments include opening new branches in international markets and focusing on regulatory registrations in countries like Thailand, Mexico, Taiwan, Brazil, EU, and Australia.
→Investments are ongoing in South India with a significant team presence being established.
→There is a focus on product registrations and international patents to support future growth.
→Marketing and farmer engagement expenses are increasing as part of strategic investments, particularly for branded and patented products.
→The overall approach to CAPEX is growth-oriented, with upcoming financing plans to support expansion and stabilization of the balance sheet.

How does Best Agrolife Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Best Agrolife Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Best Agrolife Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio